ABE1338
Anti-METTL14 Antibody
from rabbit, purified by affinity chromatography
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
N6-adenosine-methyltransferase subunit METTL14, m6A methyltransferase METTL14, Methyltransferase-like protein 14
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, human
species reactivity (predicted by homology)
zebrafish (based on 100% sequence homology), rat (based on 100% sequence homology)
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
target post-translational modification
unmodified
Gene Information
human ... METTL14(57721)
General description
N6-adenosine-methyltransferase subunit METTL14 (EC 2.1.1.62; UniProt Q9HCE5; also known as m6A methyltransferase METTL14, Methyltransferase-like protein 14) is encoded by the METTL14 (also known as KIAA1627) gene (Gene ID 57721) in human. N(6)-Methyladenosine (m(6)A) represents the most prevalent internal modification in messenger and long noncoding RNAs. This reversible modification is installed by the m(6)A methylation "writers" and remomved by demethylases that serve as "erasers. In addition, methyl-specific binding proteins, primarily of the YTH-domain family, function as "readers" and mediate the effect by binding to modified transcripts. METTL14 is a component of the nuclear methyltransferase complex (writers) composed of METTL3, METTL14, and WTAP. At least 2 demethylases (erasers), ALKBH5 and FTO, that can catalyze the reverse reaction. The roles of m(6)A in cell fates regulation and embryonic development highlight the existence of another layer of epigenetic regulation at the RNA level.
Specificity
The immunogen sequence is present in human METTL14 (UniProt Q9HCE5) and both of murine METTL14 spliced isoforms (Uniprot Q3UIK4).
Immunogen
KLH-conjugated linear peptide corresponding to an internal sequence from the C-terminal half of human METTL14.
Application
This Anti-METTL14 Antibody is validated for use in Western Blotting for the detection of METTL14.
Quality
Evaluated by Western Blotting in Raji nuclear extract.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected METTL14 in 10 µg of Raji nuclear extract.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected METTL14 in 10 µg of Raji nuclear extract.
Target description
~56 kDa observed. 52.15 kDa (human), 52.12/40.72 kDa (mouse isoform 1/2) calculated. Uncharacterized band(s) may appear in some lysates.
Other Notes
Concentration: Please refer to lot specific datasheet.
recommended
Product No.
Description
Pricing
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling.
Rethnam, et al.
Blood advances, 6, 5330-5344 (2023)
Fanpeng Zhao et al.
Molecular neurodegeneration, 16(1), 70-70 (2021-10-02)
N6-methyladenosine (m6A) modification of RNA influences fundamental aspects of RNA metabolism and m6A dysregulation is implicated in various human diseases. In this study, we explored the potential role of RNA m6A modification in the pathogenesis of Alzheimer disease (AD). We
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service